Lantern Pharma Inc. is a clinical stage biotech firm that uses AI, machine learning, and genomic data to simplify drug development. Their LP-100 is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer, while LP-300 is in development as a combo therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. Finally, LP-184 is their pre-clinical drug candidate that damages DNA in cancer cells, while the company's ADC program offers an antibody drug conjugate approach to cancer therapy.